ClinicalTrials.gg
CompletedNCT04468815Updated May 10, 2022

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

A Phase 1 interventional study of BMS-986278 Tablet and Esomeprazole in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-10.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2020, 6 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess levels in blood plasma of BMS-986278 and the food effect in healthy participants.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants, as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations in the opinion of the investigator
  • Women and men must agree to follow specific methods of

Exclusion criteria

Exclusion Criteria:

  • Women of (WOCBP) and Women who are pregnant or breastfeeding
  • Any significant acute or chronic medical condition that presents a potential risk to the participant and/or that may compromise the objectives of the study
  • Exposure to any drug or placebo within 4 weeks of first study treatment administration.
  • History of any significant drug and/or food allergies (such as anaphylaxis or hepatotoxicity)

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment A: BMS-986278 suspension, fasted

    Drug: BMS-986278 suspension

  • Experimental
    Treatment B: BMS-986278 tablet, fasted

    Drug: BMS-986278 Tablet

  • Experimental
    Treatment C: BMS-986278 tablet, fed

    Drug: BMS-986278 Tablet

  • Experimental
    Treatment D: BMS-986278 tablet + esomeprazole capsule, fasted

    Drug: BMS-986278 Tablet · Drug: Esomeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of BMS-986278

    Time frame: Up to 5 days

  2. Area under the concentration-time curve from time 0 (dosing) to the time of the last quantifiable concentration observed (AUC(0-T) of BMS-986278

    Time frame: Up to 5 days

  3. Area under the concentration-time curve from time 0 (dosing) extrapolated to infinity AUC (INF) of BMS-986278 from the respective test treatments

    Time frame: Up to 5 days

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Up to 29 days

  2. Incidence of Serious Adverse (SAE's)

    Time frame: Up to 57 days

  3. Incidence of AEs leading to discontinuation

    Time frame: Up to 29 days

  4. Incidence of clinically significant changes in vital signs: Blood pressure

    Time frame: Up to 48 days

  5. Incidence of clinically significant changes in vital signs: Heart rate

    Time frame: Up to 48 days

  6. Incidence of clinically significant changes in vital signs: Respiratory rate

    Time frame: Up to 48 days

  7. Incidence of clinically significant changes in vital signs: Body temperature

    Time frame: Up to 48 days

  8. Incidence of clinically significant changes in electrocardiogram (ECG) parameters

    Time frame: Up to 48 days

  9. Incidence of clinically significant changes in physical examination findings

    Time frame: Up to 48 days

  10. Incidence of clinically significant changes in clinical laboratory results: Clinical chemistry tests

    Time frame: Up to 48 days

  11. Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests

    Time frame: Up to 48 days

  12. Incidence of clinically significant changes in clinical laboratory results: Hematology tests

    Time frame: Up to 48 days

07

Study locations

1 site
  • ICON (LPRA) - Salt Lake
    Salt Lake City, Utah 84124, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Oct 2020, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2020
First posted
Jul 13, 2020
StartActual
Jul 10, 2020
Primary completionActual
Oct 7, 2020
CompletionActual
Oct 7, 2020
Last update
May 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04468815
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
Jul 10, 2020
Primary completion
Oct 7, 2020
Completion
Oct 7, 2020
Last update
May 10, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Admilparant

Start the discussion